Conformis Inc. (NASDAQ: CFMS) stock declined by 4.44% at the last close whereas the CFMS stock price gains by 3.1% in the after-hours trading session. Conformis is a medical technology company that develops, manufactures, and sells joint replacement implants and instruments that are separately sized and shaped, also known as personalised, individualised, or customised, to fit and ensure adherence to each person’s specific anatomy using its proprietary iFit Image-to-Implant technology platform.

CFMS stock’ Update

Conformis today revealed the positive findings of a retrospective analysis of operations performed using Conformis’ patient-specific iTotal CR (cruciate-retaining) knee replacement implant, which looked at implant survival, patient satisfaction, and functional outcomes.

The clinical study’s main findings are as follows:

• At a mean follow-up of 2.8 years, implant survival was 98.5 percent, with 8 revisions (representing 1.5 percent of the 540 implants examined) (ranging from one month to seven years post-surgery).
• Patient Satisfaction – 89 percent of patients said they were pleased or very satisfied with their care.
• Functional Results — The Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR) questionnaire yielded a strong mean score of 82 (range: 34-100).

Furthermore,

The researchers examined patient records and performed patient report outcome surveys on 540 knees in 433 patients who underwent personalised total knee arthroplasty at Personalized Orthopaedics of the Palm Beaches in Boynton Beach, Florida, performed by Dr. Gregory Martin, a U.S. board-certified orthopaedic surgeon. The demographics of the patients, surgical factors, complications, and re-operations were all taken into account. To measure survival, patient satisfaction, and functional results, follow-up evaluations were conducted via a single phone call.

Mark Augusti, President, and CEO of Conformis stated,

This research was one of the biggest retrospective studies they’ve ever done, and it’s another evidence of how their technology leads to high patient satisfaction, excellent functional results, and long-term implant survival. This is a tribute to their whole organization’s commitment to providing high-quality products to their clients and their patients. This helps their long-term growth plan while reinforcing the mission.